Portal de Periódicos da CAPES

Salvage chemotherapy followed by granulocyte colony‐stimulating factor‐primed donor leukocyte infusion with graft‐vs.‐host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes

2015; Wiley; Volume: 96; Issue: 3 Linguagem: Inglês

10.1111/ejh.12591

1600-0609

Xiao‐Dong Mo, Xiao‐Hui Zhang, Lan‐Ping Xu, Yu Wang, Chen‐Hua Yan, Huan Chen, Yu‐Hong Chen, Wei Han, Feng‐Rong Wang, Jingzhi Wang, Kai‐Yan Liu, Xiao‐Jun Huang,

Neutropenia and Cancer Infections

Abstract This study investigated the prognostic factors and clinical outcomes of preemptive chemotherapy followed by granulocyte colony‐stimulating factor‐primed donor leukocyte infusion (Chemo‐ DLI ) according to minimal residual disease ( MRD ) status in patients with acute leukemia and myelodysplastic syndromes who received allogeneic hematopoietic stem cell transplantation ( HSCT ) ( n = 101). Patients received immunosuppressive drugs to prevent graft‐vs.‐host disease ( GVHD ) after Chemo‐ DLI . The 3‐yr cumulative incidences of relapse, non‐relapse mortality, and disease‐free survival ( DFS ) after HSCT were 39.5%, 9.6%, and 51.7%, respectively. The cumulative incidences of relapse and DFS were significantly poorer in patients who exhibited early‐onset MRD . Forty‐four patients turned MRD negative 1 month after Chemo‐ DLI ; their cumulative incidences of relapse and DFS were significantly better than those with persistent MRD 1 month after preemptive Chemo‐ DLI (relapse: 19.8% vs. 46.8%, P = 0.001; DFS : 69.6% vs. 46.4%, P = 0.004). The cumulative incidences of relapse and DFS after HSCT were significantly better in patients with chronic GVHD ( cGVHD ) than those without cGVHD (relapse: 19.6% vs. 63.7%, P < 0.001; DFS : 74.4% vs. 23.8%, P < 0.001). Early‐onset MRD , persistent MRD after Chemo‐ DLI , and non‐ cGVHD after Chemo‐ DLI , which were associated with increased relapse and impaired DFS , suggest unsatisfactory response to preemptive Chemo‐DLI.